Welcome to our dedicated page for Eledon Pharmaceuticals SEC filings (Ticker: ELDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eledon Pharmaceuticals SEC filings document the governance, financing and clinical-development disclosures of a clinical-stage biotechnology issuer centered on tegoprubart. Proxy materials cover shareholder voting matters, board and compensation governance, equity awards and executive compensation disclosures.
Material-event filings report operating results and financial condition, Regulation FD clinical updates, presentations and press-release exhibits related to tegoprubart programs in transplantation. The filing record also includes disclosure categories tied to material agreements, capital structure, shareholder matters and clinical or regulatory developments for the company’s anti-CD40L development strategy.
Eledon Pharmaceuticals reported a net loss of $31.6 million for the quarter and $70.7 million for the six months ended June 30, 2026, driven mainly by research and development expenses of $35.4 million and general and administrative costs of $8.6 million in the first half.
Cash, cash equivalents and short-term investments totaled $88.8 million, with working capital of $81.3 million, but operating activities used $45.3 million of cash in the six-month period. Management states that, based on the current operating plan, existing resources are not sufficient for the next 12 months, and there is substantial doubt about the ability to continue as a going concern without additional financing.
The company remains a clinical-stage biotech focused on tegoprubart for kidney transplantation and ALS. Capital structure is complex, with $40.0 million of warrant liabilities and outstanding preferred stock and pre-funded warrants contributing to a total accumulated deficit of $471.9 million as of June 30, 2026.
Eledon Pharmaceuticals reported second quarter 2026 results and highlighted progress with its lead anti-CD40L antibody, tegoprubart. An End-of-Phase 2 meeting with the FDA supports advancing a global Phase 3 kidney transplantation trial enrolling approximately 600 patients, with non-inferiority to tacrolimus at 52 weeks as the primary endpoint. Long-term Phase 2 BESTOW data showed mean eGFR of 74 vs. 61 mL/min/1.73 m² for tegoprubart versus tacrolimus at 18 months, with no biopsy-proven acute rejection events after six months in tegoprubart-treated patients. In an islet cell transplantation study, all 12 patients with type 1 diabetes achieved insulin independence and HbA1c below 6.5%. Cash, cash equivalents and short-term investments were $88.8 million as of June 30, 2026, and the company expects this to fund operations into the second quarter of 2027. R&D expense was $18.2 million, G&A was $4.6 million, and net loss was $31.6 million, including a $9.6 million non-cash loss from warrant liability remeasurement.
Eledon Pharmaceuticals, Inc. reports that Chief Executive Officer David-Alexandre C Gros received 354,454 shares of common stock on 2026-07-31 as settlement of a retention bonus award under an agreement entered into on 2023-04-27. On the same date, 194,791 shares were withheld at $3.38 per share to satisfy tax withholding obligations related to this settlement, resulting in a mix of stock compensation and tax-withholding dispositions.
Eledon Pharmaceuticals, Inc. reported that President Steven Perrin received 152,353 shares of Common Stock on 2026-07-31 upon settlement of a retention bonus award, under an agreement entered into on April 27, 2023. On the same date, 72,138 shares were withheld at $3.38 per share to satisfy tax withholding obligations.
Vanguard Capital Management reports a passive ownership stake in Eledon Pharmaceuticals Inc. common stock on a Schedule 13G. Vanguard Capital Management and specified affiliated entities beneficially own 3,898,446 shares, representing 5.05% of Eledon’s outstanding common stock.
They have sole voting power over 481,223 shares and sole dispositive power over all 3,898,446 shares, with no shared voting or dispositive power. The filing explains that the position aggregates holdings of various Vanguard funds and managed accounts over which Vanguard entities exercise dispositive and/or voting authority, while excluding other Vanguard affiliates whose ownership is disaggregated under SEC guidance.
The filing also notes that Vanguard-managed investment companies and other accounts have the right to receive dividends and sale proceeds from the reported securities, and that no single other person has an interest in more than 5% of the class.
Eledon Pharmaceuticals, Inc. reported that stockholders approved key actions at the June 18, 2026 annual meeting. Investors voted to amend the company’s Restated Certificate of Incorporation to increase authorized common stock from 300,000,000 to 450,000,000 shares, and the company filed a Certificate of Amendment in Delaware effective June 22, 2026.
Stockholders also elected David-Alexandre C. Gros, M.D., Jan Hillson, M.D., and James Robinson as Class III directors for terms ending at the 2029 annual meeting. In addition, they ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026.
Eledon Pharmaceuticals: Schedule 13G/A filing reporting aggregated beneficial ownership by Biotechnology Value Fund group. As of the close of business on March 31, 2026, the Reporting Persons and a Partners managed account hold convertible securities and warrants that, subject to multiple 9.99% ownership blockers, translate into convertible and exercisable positions described below.
The filing lists aggregate holdings including 5,382,084 Shares beneficially owned by BVF, 2,057,090 Shares by BVF2, and various convertible instruments: 4,419.93 shares of Series X Preferred (convertible into 245,552 Shares), 87,607.152 shares of Series X1 Preferred (convertible into 4,867,067 Shares), 15,247,782 Pre-Funded Warrants (exercisable into 15,247,782 Shares), and 5,844,153 Tranche A Warrants. The filing explains conversion/exercise blockers that currently limit conversion or exercise into Shares.
Eledon Pharmaceuticals reports results for the quarter ended March 31, 2026, highlighting continued investment in its lead antibody tegoprubart for transplantation and ALS. The company posted a net loss of $39.0 million, compared with $6.5 million a year earlier, largely driven by a non-cash $19.0 million increase in warrant liabilities.
Operating expenses rose to $21.2 million, mainly from higher research and development spending of $17.2 million linked to kidney transplant programs and manufacturing. Cash used in operating activities was $22.6 million. Eledon ended the quarter with $111.1 million in cash, cash equivalents and short-term investments and working capital of $100.1 million, and expects these resources to fund planned operations for at least 12 months.
The balance sheet reflects $32.4 million of in-process R&D from the Anelixis acquisition and $30.4 million of warrant liabilities measured at fair value. Management reiterates that additional capital will ultimately be needed to complete development of tegoprubart, and the risk factor section emphasizes ongoing losses, funding needs, clinical and regulatory uncertainties, and competitive pressures typical for a clinical-stage biotech.
Eledon Pharmaceuticals reported first quarter 2026 results and progress for its lead antibody tegoprubart. In an investigator-led islet transplant study, all 10 patients who were more than four weeks post-transplant achieved 100% insulin independence with no graft rejection or typical tacrolimus-related toxicities. Tegoprubart also received FDA Orphan Drug designation for preventing allograft rejection in liver transplantation.
In kidney transplantation, 24‑month Phase 1b extension data in eight patients showed no biopsy‑proven acute rejection, graft loss, death, new-onset diabetes, or de novo donor‑specific antibodies, and mean eGFR improved from 67.0 to 74.2 mL/min/1.73 m². Cash, cash equivalents and short‑term investments were $111.1 million as of March 31, 2026, which the company believes will fund operations into the second quarter of 2027.
R&D expenses were $17.2 million versus $13.5 million a year earlier, while G&A was $4.0 million versus $4.4 million. Net loss was $39.0 million, or $0.33 per common share, compared with $6.5 million, or $0.08 per share, mainly due to a $19.0 million non‑cash loss from warrant liabilities versus a $10.1 million non‑cash gain in 2025; excluding these, net loss was $20.1 million versus $16.6 million.